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COST-EFFECTIVENESS OF TNF-ALPHA BLOCKERS IN REAL-WORLD 
SETTING OF CZECH REGISTRY
Dolezal T1, Petrikova A2, Pavelka K3
1Charles University, 3rd Medical Faculty, Prague, Czech Republic, 2University of Veterinary 
and Pharmaceutical Sciences Brno, Brno, Czech Republic, 3Charles University, Rheumatology 
Institute, Prague, Czech Republic
OBJECTIVES: Recently the LUNDEX index as a composite measure of therapeutic 
response and adherence on treatment was introduced to rheumatology.The objective 
of our study was to assess the cost-effectiveness of TNF-alpha blockers (inﬂiximab-
INF, adalimumab-ADA and etanercept-ETA) in Czech Republic based on real-world 
data from ATTRA registry. METHODS: Therapeutic response and the adherence data 
were derived from Czech registry of biologics in rheumatoid arthritis (ATTRA). The 
time horizon was 12 months. The response criterion used in this analysis was the 
remission based on EULAR deﬁnition (DAS28  2.6). The direct health care costs 
including the cost of administration during 12 months were calculated. RESULTS: 
Drug and administration costs for the payer during 12 months were 428,901 CZK 
(a16,437) for etanercept, 454,203 CZK (a17,467) for inﬂiximab and 455,270 CZK 
(a17,510) for adalimumab. For calculation of the cost per LUNDEX-response over 
12 months the total costs were divided by the LUNDEX-response. The results for each 
TNF-a blocker are shown in table as ETA: 0.83, 0.282, 0.23, 71,723EUR; INF: 0.78, 
0.129, 0.10, 174,670EUR; ADA: 0.81, 0.178, 0.14, 125,074EUR for Therapy adher-
ence, Proportion of patients in remission, LUNDEX response, Cost/LUNDEX per 12 
months where 1 EUR  26 CZK. The average cost per LUNDEX-responder month 
are were calculated by dividing the costs/LUNDEX per 12 months by 12. The results 
are a5977 for etanercept, a14,556 for inﬂiximab and a10,423 for adalimumab. CON-
CLUSIONS: The LUNDEX is useful tool for evaluating the effectiveness of TNF-alpha 
blockers in real-world clinical practice and biologics registries combining two impor-
tant dimensions (adherence and response). From the perspective of Czech registry 
ATTRA etanercept seems to be the most cost-effective option.
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HEALTH ECONOMIC EVALUATION OF THE TREATMENT OF 
OSTEOPOROSIS IN FIVE ITALIAN REGIONS
Baio G1, Di Tanna GL2, Integlia D3, Pammolli F4
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OBJECTIVES: Oral bisphosphonates (OB) represent the standard treatments for 
osteoporosis, but despite their proven effectiveness in clinical trials, they have shown 
signiﬁcant problems with compliance in clinical practice. The objective of this paper 
is to study the cost-effectiveness (CE) of Zoledronic Acid (Zol) a molecule still belong-
ing to the category of bisphosphonates, but whose administration route is intravenous. 
Due to this circumstance, treatment with Zol potentially overcomes the limitations of 
OB, since patients are treated once a year with a single infusion. METHODS: We use 
a Bayesian Markov model and perform a CE analysis integrating evidence from dif-
ferent sources, such as published data on clinical outcomes and ofﬁcial records on 
population, mortality and morbidity; the costs considered are for hospitalisations, 
pharmacological treatment and rehabilitation. Uncertainty is propagated through the 
model using MCMC based algorithms. The validity of the results is checked using 
Probabilistic Sensitivity Analysis, summarised by means of the Cost-effectiveness 
acceptability curve (CEAC) and the Expected value of information (EVI). RESULTS: 
In all the 5 regions analysed, Zol tends to reduce the number of re-fractures (24% 
in Lombardia, with similar ﬁgures in the other regions), due to its higher compliance. 
Despite higher costs for treatment, Zol produces net savings in all the regions. The 
analysis of CEAC shows that the uncertainty related to the CE of Zol is limited in all 
the regions (with willingness to pay as low as a12,000, the posterior probability of 
CE reaches values as high as 0.96 in comparison with OB). The EVI analysis also 
shows that the value of acquiring additional information to limit uncertainty in the 
CE is limited. CONCLUSIONS: Zoledronic Acid proves to be an interesting alterna-
tive to OB, capable of overcoming their limitations in terms of compliance with 
treatment.onal information to limit uncertainty in the CE is limited.
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ECONOMIC EVALUATION OF GLUCOSAMINE SULPHATE TREATMENT 
IN KNEE OSTEOARTHRITIS
Simoens S
Katholieke Universiteit Leuven, Leuven, Belgium
OBJECTIVES: This study aims to conduct a cost-effectiveness analysis of glucosamine 
sulphate treatment as compared to placebo in knee osteoarthritis from the Belgian 
health care system perspective. The economic evaluation investigates whether the drug 
acquisition costs of patients receiving glucosamine sulphate treatment are balanced 
by a lower incidence of total knee replacement and reduced hospitalization costs. 
METHODS: The study collected Belgian cost data and derived effectiveness data from 
a long-term follow-up of patients with knee osteoarthritis. Two randomised, placebo-
controlled, double-blind trials compared patients who had received oral glucosamine 
sulphate 1500 mg once-a-day for up to 3 years with patients who had received 
placebo. Patients who had participated in these two trials and who had received at 
least one year of treatment were enrolled in a retrospective assessment of the incidence 
of total knee replacement during a ﬁve-year follow-up period. The price year was 
2006. RESULTS: The sample consisted of 131 patients who had formerly received 
placebo and 144 patients who had formerly received glucosamine sulphate. The 
number of patients undergoing total knee replacement during the 5-year follow-up 
amounted to 19 patients (14.5%) in the former placebo group and 9 patients (6.3%) 
in the former glucosamine sulphate group. Health care costs per patient amounted to 
a1103 in the former placebo group and a901 in the former glucosamine sulphate 
group. CONCLUSIONS: Treatment of knee osteoarthritis with glucosamine sulphate 
for at least one year and up to three years was associated with a lower incidence of 
total knee replacement and lower health care costs over an observation period of eight 
years as compared with placebo.
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COST-EFFECTIVENESS OF BALLOON KYPHOPLASTY IN PATIENTS 
WITH SYMPTOMATIC VERTEBRAL COMPRESSION FRACTURES IN A 
UK SETTING
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OBJECTIVES: Vertebral compression fractures (VCFs) in osteoporotic patients are 
associated with chronic pain, a reduction in health-related quality of life (QoL) and 
high health care costs. Balloon Kyphoplasty (BKP) is a minimally invasive procedure 
that has resulted in pain relief, vertebral body height-restoration, and improved physi-
cal functioning in patients with symptomatic VCFs. BKP was shown to improve 
health-related QoL in a 12-month analysis of a randomised phase-III trial. The objec-
tive of this study was to estimate the cost-effectiveness of BKP compared to non-
 surgical management in a UK setting. METHODS: A Markov cost-effectiveness model 
was constructed to evaluate BKP after painful hospitalised VCFs from a health care 
perspective. The model was populated with relevant epidemiology and cost data. It 
was assumed that QoL-beneﬁts found at 12 months linearly approached zero during 
the following 24 months and that patients receiving BKP required 6 less hospital bed-
days compared to patients given non-surgical management. No reduction of future 
fracture risk was assumed. The cost of the BKP devices and procedure was £2690 and 
£1400, respectively. A 43% reduction in mortality during the ﬁrst year after the pro-
cedure was explored in sensitivity analysis. RESULTS: The procedure was in the 
base-case associated with estimated QALY-gains of 0.17 and cost/QALY of £8800 in 
70 year old patients. Results marginally deteriorated with increasing age at the time 
of surgery due to higher mortality and fracture rates, both of which shorten the 
accrued beneﬁt of BKP. Inclusion of a mortality reduction resulted in 0.448 life years 
gained per patient and a cost/QALY of £4600. The results were also sensitive to 
assumptions about the cost of the procedure, avoided length of hospital-stay and 
persistence of balloon kyphoplasty-related QoL-beneﬁts. CONCLUSIONS: The 
results indicate that BKP provides a cost-effective alternative for treating patients with 
hospitalised VCFs in a UK-setting.
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OBJECTIVES: The primary objective was to determine and analyze the indirect costs 
associated with rheumatoid arthritis (RA) before and after six months of treatment 
with TNFA blockers. The secondary objective was to evaluate the impact of health 
condition improvement, assessed using Health Assessment Questionnaire (HAQ) ques-
tionnaire, on the indirect costs after treatment. METHODS: The study was a retro-
spective-longitudinal cost analysis and reﬂects the common practice of using anti-TNFA 
drugs. Indirect costs before and after anti-TNFA therapy initiation were recorded then 
compared in order to estimate the decrease in indirect costs due to the use of TNFA 
blockers. Patients were asked to provide information on working days lost in the six 
months preceding the enrollment; and followed up for six months after starting anti-
TNFA therapy. Costs were quantiﬁed using Human Capital Approach method and 
considering the societal perspective. A zero inﬂated negative binomial model was 
adopted to evaluate the effect of HAQ improvement adjusting by demographic data 
and other factors that inﬂuence indirect costs RESULTS: The mean cost per month 
per patient before and after the starting therapy with anti-TNFA was a343.18 and 
a58.92, respectively (p  0.0001). HAQ improvement was to be associated with a 
decreasing risk to incur indirect costs. CONCLUSIONS: Our data links the indirect 
costs due to the disease mostly to its impact on function and degree of disability of 
the patients. Our results showed that anti-TNFA therapy is effective even in the short 
term this is mainly attributable to the dramatic improvement in functional status and, 
consequently, in quality of life. This improvement can be translated in monetary terms. 
Results suggest that anti-TNFA can dramatically decrease the indirect costs of RA, 
and the amount of saved resources will be increased if patients are promptly treated 
thus avoiding disease progression.
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CARDIOVASCULAR SAFETY PROFILE OF NSAIDS
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OBJECTIVES: To quantify potential cost savings and quality adjusted life year 
(QALY) gains of improving the blood pressure (BP) proﬁle of non-steroidal anti 
inﬂammatory drugs (NSAIDs). METHODS: Increasing attention has been paid to the 
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cardiovascular (CV) risk of NSAIDs, partially triggered by the withdrawal of rofe-
coxib. Small increases in BP associated with NSAID use contribute to the CV toxicity 
of NSAIDs. OA patients often have an elevated risk for CV events due to characteris-
tics common to this population; advanced age, obesity, and co-morbidities such as 
diabetes, hypertension and other CV risks. In order to quantify the potential health 
economic beneﬁts of improvement in the BP proﬁle of NSAIDs, an individual state 
transition model (one year cycles, 5-year treatment duration, life-time model horizon, 
health care perspective) encompassing eight CV events (congestive heart failure, stroke, 
transient ischemic attack, myocardial infarction, stable angina, unstable angina, stroke 
death and MI death) caused or exacerbated by increases in BP was constructed. The 
model was populated with UK data. The model was used to estimate potential cost 
savings and QALY beneﬁts from avoided cardiovascular events associated with four 
levels of relative risk reductions (RRRs) with a hypothetical NSAID (5%, 10%, 15%. 
20% and 25%) compared to naproxen—widely regarded the NSAID with the most 
benign CV proﬁle currently on the market—at three levels of absolute 10-year primary 
CV risk (20%, 30% and 40%). RESULTS: As expected the cost savings and QALY 
beneﬁts associated with avoided cardiovascular events increased with the level of RRR 
and 10-year absolute CV risk. Potential cost savings ranged from GBP 181 to GBP 
1,591, whereas the QALY beneﬁts ranged from 0.05 to 0.44. CONCLUSIONS: An 
NSAID with an improved BP proﬁle has the potential to provide signiﬁcant health 
economic beneﬁts, especially in patients with elevated CV risk.
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PHARMACOECONOMIC MODEL FOR TREATING OSTEOPOROSIS WITH 
ALPHACALCIDOL IN GERMANY
Andersen SH, Ryttov J, Nielsen S
LEO Pharma, Ballerup, Denmark
OBJECTIVES: Analyse the costs and outcome of treating osteoporosis in Germany 
with either a combination of Alfacalcidol, Alendronate and 500 mg calcium (regime 
1) or plain vitamin D, Alendronate and 1000 mg calcium (regime 2). METHODS: A 
Markov model was created and a time horizon of 2, 5 and 10 years were evaluated. 
Patients could be in the state of well, fracture, post fracture and dead. Data were 
extracted from published clinical trials and register based studies. RESULTS: Treat-
ment regime 1 are associated with lower costs compared to treatment regime 2. The 
drug costs in regime 1 are above the drug costs in regime 2 (a2191/patient vs. a1392/
patient). However, when taking into account that the risk of fractures is signiﬁcantly 
lower for patients treated in regime 1, treatment regime 1 becomes cost saving over 
a 2 year time horizon compared to regime 2 (a3142/patient vs. a4782/patient). Regime 
1 is also the most effective alternative measured in QALYs. On a 2 year time horizon 
the patients in treatment regime 1 gain 1.4956 QALYs. In comparison, patients from 
regime 2 gains 1.4242 QALYs, i.e. regime 1 is dominating regime 2. In 2003, around 
7.8 million Germans, or around 25% of the population above the age of 50, were 
estimated to suffer from osteoporosis. Taking into account the savings per patient 
when treating with regime 1, there is a signiﬁcant saving potential for Germany. 
CONCLUSIONS: Lowest total cost of treatment is obtained when osteoporosis 
patients are treated with Alfacalcidol in combination with Alendronate and 500 mg 
calcium. Even though the initial cost of plain vitamin D, Alendronate 1000 mg 
calcium is lower, the Alfacalcidol regime is more cost effective, due to a signiﬁcantly 
lower risk of fractures. Furthermore, the Alfacalcidol regime is more effective mea-
sured in QALYs.
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COST-UTILITY ANALYSIS OF LEFLUNOMIDE (ARAVA) IN THE 
TREATMENT OF RHEUMATOID ARTHRITIS (RA) IN POLAND
Plisko R1, Krzystek J1, Lis J2, Rys P1
1HTA Consulting, Krakow, Poland, 2Sanoﬁ-Aventis, Warsaw, Poland
OBJECTIVES: To evaluate the cost-effectiveness of leﬂunomide used before tumor 
necrosis factor (TNF) inhibitors compared with leﬂunomide after TNF inhibitors in 
the sequence treatment of rheumatoid arthritis (RA) following the failure of 2 disease-
modifying antirheumatic drugs (DMARDs) in Polish setting. METHODS: A cost-
utility approach was adopted, evaluating total direct costs incurred by the National 
Health Fund (NHF) and quality-adjusted life years (QALY). A micro-simulation 
Markov model was used to estimate utilities and costs. Simulation was executed in 6 
months cycles and terminated at the time of the patient’s death. Transition probabili-
ties between health states were calculated based on a systematic review of RCTs and 
supplemented with published literature if necessary. Health states utilities were taken 
from published literature. Probabilistic sensitivity analysis was performed. The starting 
time-point of the model was the failure of two previous DMARDs. Six treatment 
options were compared. Upon treatment failure it was assumed patients would follow 
an identical lifetime treatment strategy consisting of: LIM—leﬂunomide, inﬂiximab, 
methotrexat, LEM—leﬂunomide, etanercept, methotrexat, LAM—leﬂunomide, adali-
mumab, methotrexat, ILM—inﬂiximab, leﬂunomide, methotrexat, ELM—etanercept, 
leﬂunomide, methotrexat, ALM—adalimumab, leﬂunomide, methotrexat. RESULTS: 
Sequences with leﬂunomide at the beginning of the RA treatment (LIM, LAM, LEM) 
were dominant over schedules with leﬂunomide used after TNF inhibitors (ILM, ELM, 
ALM). Detailed results: LIM vs. ILM (cost difference—7,788 PLN, QALY difference 
—0.002); LEM vs. ELM (cost difference—18,871 PLN, QALY difference—0.004); 
LAM vs. ALM (cost difference—11,377 PLN, QALY difference—0.016). CONCLU-
SIONS: The model predicted that leﬂunomide should be used before TNF inhibitors. 
LEM, LAM, LIM sequences for RA patients who have failed DMARDs therapy are 
less costly and more effective than sequences with leﬂunomid administrated after TNF 
inhibitors (ILM, ELM, ALM).
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COST-MINIMIZATION ANALYSIS OF BISPHOSPHONATES FOR RISK 
REDUCTION OF POST-MENOPAUSE VERTEBRAL AND NON-
VERTEBRAL FRACTURES UNDER THE PUBLIC PAYER PERSPECTIVE  
IN BRAZIL
Saggia MG, Paschoalin MA, Santos EA, Borges LG
Roche Brazil, Sao Paulo, SP, Brazil
INTRODUCTION: Osteoporosis is a common illness frequently leading to serious 
adverse outcomes for patients. Hip, wrist and vertebral fractures have considerable 
impact on both costs to health care system and lives of those who suffer from those 
events. Each year in the US, an estimated 1.5 million fractures occur due to osteopo-
rosis [Riggs and Melton, 1995]. Estimated incremental cost of osteoporosis related 
events in subsequent years after fracture is US$4.007 [Rousculp, 2007]. Bisphospho-
nates are widely used and are considered an effective intervention for risk reduction 
of postmenopausal fractures. OBJECTIVES: The present study was conducted to 
compare the cost of bisphosphonates used for risk reduction of post-menopause ver-
tebral and non-vertebral fractures under public payer (SUS) perspective in Brazil. 
METHODS: The most important bisphosphonates in the public market are ibandro-
nate (oral and IV), zolendronate, alendronate and risendronate. There are no head-
to-head clinical trials comparing all compounds. Studies of ibandronate IV [Eisman, 
2008] and zolendronate IV [McClung, 2007] demonstrated their non-inferiority 
against oral bisphosphonates. Therefore, a cost-minimization approach was taken. 
Drug acquisition costs took into account was the maximum sales price to government. 
Administration costs were obtained from SUS reimbursement database (SIA/SUS, 
2006). Since the time horizon of this analysis is one-year, no discount rate was utilized. 
Costs are presented in Brazilian Reais (US$1.00^R$2.00 in May 2009). RESULTS: 
Total cost per patient was R$814.12 for IV ibandronate, R$915.59 for alendronate, 
R$1054.32 for oral ibandronate, R$1054.97 for zolendronate and R$1278.81 for 
risendronate. Administration costs represented about 9% and 2% of total cost of 
ibandronate (administrated four times a year) and zolendronate (administrated once 
a year), respectively. CONCLUSIONS: Findings suggest IV ibandronate is a cost-
saving therapy with potential of reducing total treatment cost per patient from 11% 
to 36%, when compared to alendronate and risedronate respectively, under public 
payer perspective.
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REDUCTION OF POST-MENOPAUSE VERTEBRAL AND NON-
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IN BRAZIL
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BACKGROUND: Osteoporosis is a common illness frequently leading to serious 
adverse outcomes for patients. Hip, wrist and vertebral fractures have considerable 
impact on both costs to health care system and lives of those who suffer from those 
events. Each year in the US, an estimated 1.5 million fractures occur due to osteopo-
rosis [Riggs and Melton, 1995]. Estimated incremental cost of osteoporosis related 
events in subsequent years after fracture is US$4007 [Rousculp, 2007]. Bisphospho-
nates are widely used and are considered an effective intervention for risk reduction 
of postmenopausal fractures. OBJECTIVES: The present study was conducted to 
compare the cost of IV bisphosphonates used for risk reduction of post-menopause 
vertebral and non-vertebral fractures under the private payer perspective in Brazil. 
METHODS: According to local legislation, private payers are not obliged to cover 
oral drugs, therefore, oral forms of biphosphonates were not considered in this study. 
The most important IV bisphosphonates in the private market are ibandronate and 
zolendronate. There are no head-to-head clinical trials comparing both compounds. 
Both studies of ibandronate [Eisman, 2008] and zolendronate [McClung, 2007] dem-
onstrated their non-inferiority against oral bisphosphonates. Therefore, a cost-
 minimization approach was taken. Drug prices were obtained from ofﬁcial public 
sources (Kairos Magazine, May 2009). Administration costs were obtained from 
medical society physicians fee list (CBHPM, 2008, v.5). Since the time horizon of this 
analysis is one-year no discount rate was utilized. Costs are presented in Brazilian 
Reais (US$1.00^R$2.00 in May 2009). RESULTS: Total cost per patient was 
R$1534.36 for ibandronate and R$1951.26 for zolendronate. Administration costs 
represented about 11% of total cost of ibandronate (administrated four times a year) 
and 2% for zolendronate (administrated once a year). CONCLUSIONS: Findings 
suggest that IV ibandronate is a cost-saving therapy with potential to yield 21% 
reduction in total cost per patient under Brazilian private payer.
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REDUCTION OF POST-MENOPAUSE VERTEBRAL AND NON-
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IN BRAZIL
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BACKGROUND: Osteoporosis is a common illness frequently leading to serious 
adverse outcomes for patients. Hip, wrist and vertebral fractures have a considerable 
impact on both costs to health care system and lives of those who suffer from those 
events. Each year in the US, an estimated 1.5 million fractures occur due to osteopo-
rosis [Riggs and Melton, 1995]. Estimated incremental cost of osteoporosis related 
events in the subsequent years after fracture is US$4007 [Rousculp, 2007]. Bisphos-
